Merck's Keytruda received FDA approval for ovarian cancer and Agilent earned FDA clearance for a companion diagnostic to identify patients likely to benefit.
Longevity News
As Merck received its latest FDA nod for Keytruda in ovarian cancer, Agilent gained the green light for its accompany...
Source: FierceBiotech - Medtech • Published: 19 Feb 2026, 22:00
Continue exploring
Related longevity signals
Frontiers - HealthIntegrated CDK4/6 Inhibitor Resistance and Primary-Metastatic Discordance in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: A Translational Framework Focused on Invasive Ductal Carcinoma With Gastric MetastasisPresents a translational framework linking genomic resistance signatures and primary‑metastatic phenotype discordance in HR+/HER2‑ metastatic breast cancer focusing on invasive ductal carcinoma with gastric spread.Nature - BiotechnologySpirulina‑mediated silver nanoparticles induce apoptosis and autophagy in Caco‑2 colorectal cancer cellsA study reports green synthesis of silver nanoparticles using a microalga extract and examines their effects on human colon cancer cells, focusing on cell death pathways.Frontiers - HealthDouble heterozygous germline pathogenic variants in patients referred to a tertiary cancer genetics clinic in SingaporeReport on the prevalence and clinical features of double heterozygous germline pathogenic variants found through multigene panels in a tertiary cancer genetics clinic.Frontiers - HealthMachine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes in Breast Cancer Histopathology: A Systematic Review and Evidence-Gap Analysis of Translational ReadinessAssessments of tumor-infiltrating lymphocytes in breast cancer using machine learning are reviewed and mapped for translational readiness and methodological gaps.